Related Experiment Videos
Octreotide in the management of hormone-refractory prostate cancer
1Department of Endocrinological Oncology, Theagenion Cancer Center, Thessaloniki, Greece.
Abstract:
Patients with advanced or metastatic prostate cancer (PC), a partially hormone-resistant disease, will require some form of hormonal manipulations or some new therapeutic modalities. Octreotide, as somatostatin (SST) analogs, has been found to inhibit the growth of experimental PCs via several mechanisms, as indirect antihormonal and direct antimitogenic actions, mainly due to inhibition of SST receptor subtypes (SSTR-1-5). Sporadic clinical trials with octreotide (alone or with a complete antiandrogen blockade) treatment of patients with advanced stage D2 PC demonstrated promising results. Unfortunately, at present these clinical trials have some disadvantages and leave some uncertainty with regard to the trial design, the SSTR subtype determination and tumor localization with SSTR scintigraphy before the start of a selective SST analog, and finally the randomization in groups according to hormone resistance, dosage regimen and route of administration.
Insights
Octreotide shows promise in treating advanced prostate cancer (PC) by inhibiting tumor growth. However, current clinical trials need refinement in design and patient stratification for optimal results.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Advanced or metastatic prostate cancer (PC) often becomes partially hormone-resistant, necessitating novel therapeutic strategies.
- Octreotide, a somatostatin (SST) analog, exhibits potential in inhibiting experimental PC growth through antihormonal and antimitogenic mechanisms.
- These mechanisms involve the inhibition of somatostatin receptor subtypes (SSTR-1-5).
Purpose of the Study:
- To evaluate the efficacy of octreotide in patients with advanced stage D2 prostate cancer.
- To explore the potential of octreotide as a therapeutic option, alone or in combination with antiandrogen therapy.
Main Methods:
- Review of sporadic clinical trials investigating octreotide treatment in advanced PC.
- Assessment of octreotide's mechanisms of action, including indirect antihormonal and direct antimitogenic effects.
- Identification of limitations in current clinical trial designs.
Main Results:
- Preliminary clinical trials with octreotide in advanced stage D2 PC patients showed promising outcomes.
- Octreotide demonstrated inhibition of PC growth via multiple mechanisms, targeting SSTR subtypes.
Conclusions:
- Octreotide presents a potential therapeutic avenue for advanced and hormone-resistant prostate cancer.
- Current clinical trial designs require improvement, particularly in SSTR subtype determination, tumor localization via SSTR scintigraphy, and patient randomization based on hormone resistance, dosage, and administration route.